title: Clindamycin in the treatment of Babesia gibsoni infections in dogs.
abstract: This report examines the effectiveness of clindamycin for the treatment of babesiosis in dogs (n=10) experimentally infected with Babesia gibsoni (B. gibsoni). Clindamycin (25 mg/kg body weight, per os, q 12 hours for 14 days) gradually reduced parasitemia levels and induced morphological changes that indicated degeneration of parasites (e.g., segmentation; size reduction; localization in the cell limbic and/or torn state of the nucleus; and swelling, decrease, or disappearance of the cytoplasm) in the majority of dogs. Clindamycin treatment reduced the clinical symptoms characteristic of Babesia infection, including anemia, anorexia, and listlessness. Clindamycin might be useful as a medicine for treatment of B. gibsoni infection.
authors.affiliation: Laboratory of Veterinary Internal Medicine, Faculty of Agriculture, Miyazaki University, Miyazaki-shi, Japan.
authors.forename: Retno
authors.initials: R
authors.lastname: Wulansari
authors.forename: Agus
authors.initials: A
authors.lastname: Wijaya
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Ano
authors.forename: Yoichiro
authors.initials: Y
authors.lastname: Horii
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Nasu
authors.forename: Shin-ichi
authors.initials: S
authors.lastname: Yamane
authors.forename: Susumu
authors.initials: S
authors.lastname: Makimura
mesh_terms: D000818:Animals; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D001403:Babesia / Q000187:drug effects*; D001404:Babesiosis / Q000188:drug therapy / Q000662:veterinary*; D002981:Clindamycin / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D008297:Male; D016896:Treatment Outcome
chemical_list: D000981:Antiprotozoal Agents; D002981:Clindamycin